Congress funds drug shortage prevention—but hands pharma firms the contracts

What it does

This bill creates a federal program where the Secretary of Health and Human Services awards contracts to pharmaceutical manufacturers, ingredient suppliers, and distributors to maintain 6-month reserves of critical drugs and active pharmaceutical ingredients with vulnerable supply chains. Participating companies receive government contracts to stockpile these reserves domestically or in OECD countries, with preference given to domestic manufacturers, and the government can direct allocation of reserves during public health emergencies or national security threats.

Why we flagged it

The bill establishes a federal contracting mechanism to build and maintain strategic reserves of critical pharmaceuticals and active ingredients, with government direction and allocation authority during emergencies. It is fundamentally a public health supply-chain intervention, not a deregulation or tax measure.

What the text implies

• The bill grants HHS broad discretion to determine which drugs are 'critical' and have 'vulnerable supply chains,' potentially creating a de facto list of government-favored products without explicit congressional approval of each selection.
• Participating manufacturers receive guaranteed government contracts and revenue streams, which may reduce competitive pressure to innovate or lower prices for non-reserve production of the same drugs.
• The provision allowing HHS to direct transfer of reserves between manufacturers (subsection (1)(C)) creates a mechanism for government-mandated technology or ingredient sharing that could affect proprietary manufacturing processes.
• Foreign establishments in OECD countries are eligible, meaning reserves may be maintained outside the U.S., potentially limiting actual domestic supply resilience during geopolitical disruptions affecting OECD partners.
• The bill authorizes $500M for FY2026 but does not cap total appropriations or specify how many drugs/manufacturers will be enrolled, creating open-ended fiscal exposure.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill directly addresses drug shortage vulnerabilities that harm patients by creating mandatory reserves of critical medications and ingredients, with government oversight and emergency allocation authority. While it channels federal spending to pharmaceutical manufacturers, the mechanism—government-directed stockpiling and allocation control—serves a clear public health purpose and reduces citizens' exposure to life-threatening drug shortages.

Who stands to gain

• pharmaceutical manufacturers (contract holders)
• active pharmaceutical ingredient producers
• drug wholesalers and distributors (as eligible entities)
• domestic manufacturing facilities and construction contractors (for facility acquisition/renovation)

Named in the bill

Secretary of Health and Human Services (HHS), Commissioner of Food and Drugs (FDA), Assistant Secretary for Preparedness and Response (ASPR), Centers for Disease Control and Prevention (CDC), Bristol Myers Squibb (BMY), Finmeccanica (FINMF), Merck & Cie (MHVYF), Fabrinet (FBIN), Johnson & Johnson (JNJ), Organisation for Economic Cooperation and Development (OECD)

Where it stands

1 cosponsor: 1 Republicans.

• Jun 12, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 12, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $800,000 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Angie Craig, the sponsor, reported $1,228,181 in PAC receipts in the 2026 cycle.

• Association for Clinical Oncology — $600,000 on 2 filings
• Phlow Corporation — $180,000 on 2 filings
• American Association of Oral and Maxillofacial Surgeons — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 18, 2026. A filing shows who paid to lobby on a bill it names, not what changed.